Moventig® is a Peripherally-Acting Mu-Opioid Receptor Antagonist (PAMORA) which is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

Moventig® 12.5 mg and 25 mg tablets
Summary of Product Characteristics
Patient Information Leaflet
European Public Assessment Report

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at
By reporting side effects you can help provide more information on the safety of these medicines.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See for how to report side effects.